Cargando…

Validation of a three-item Fatigue Severity Scale for patients with substance use disorder: a cohort study from Norway for the period 2016–2020

BACKGROUND: Little attention has been paid to customising fatigue questionnaires for patients with Substance Use Disorders (SUDs). The present study aims to validate and shorten the nine-item Fatigue Severity Scale (FSS-9) and Visual Analogue Fatigue Scale (VAFS) for use with this population. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Vold, Jørn Henrik, Gjestad, Rolf, Aas, Christer F., Meland, Eivind, Johansson, Kjell Arne, Fadnes, Lars Thore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923309/
https://www.ncbi.nlm.nih.gov/pubmed/33653349
http://dx.doi.org/10.1186/s12955-021-01708-w
_version_ 1783658882507210752
author Vold, Jørn Henrik
Gjestad, Rolf
Aas, Christer F.
Meland, Eivind
Johansson, Kjell Arne
Fadnes, Lars Thore
author_facet Vold, Jørn Henrik
Gjestad, Rolf
Aas, Christer F.
Meland, Eivind
Johansson, Kjell Arne
Fadnes, Lars Thore
author_sort Vold, Jørn Henrik
collection PubMed
description BACKGROUND: Little attention has been paid to customising fatigue questionnaires for patients with Substance Use Disorders (SUDs). The present study aims to validate and shorten the nine-item Fatigue Severity Scale (FSS-9) and Visual Analogue Fatigue Scale (VAFS) for use with this population. METHODS: We used data from a nested cohort with annual health assessments with responses on the FSS-9 and VAFS. During the period 2016–2020, 917 health assessments were collected from 655 patients with SUD in Bergen and Stavanger, Norway. A total of 225 patients answered the health assessment at least twice. We defined baseline as the first annual health assessment when the health assessments were sorted chronologically per patient. We checked for internal consistency, and we used longitudinal confirmatory factor analysis (CFA) and linear mixed model (LMM) analysis to validate and shorten the FSS-9 and VAFS. RESULTS: The internal consistency of the FSS-9 was excellent with a Cronbach’s α of 0.94 at baseline and 0.93 at the second annual health assessment. When shortening the FSS-9 to a three-item FSS (FSS-3, items 5–7), the Cronbach’s α was 0.87 at baseline and 0.84 at the second health assessment. The internal consistency was not affected when the VAFS was added to the FSS-3 and the FSS-9. The longitudinal CFA model showed a well-fitting model for the FSS-3 (χ(2) = 13.33, degree of freedom = 8, P = 0.101). The LMM analysis showed equal linear changes at the individual level for the FSS-3 (slope: 0.00, P > 0.05) and FSS-9 (slope: 0.01, P > 0.05) between the health assessments. CONCLUSION: The FSS-9 could be shortened to the FSS-3 with high validity and reliability for patients with SUDs and the addition of VAFS did not provide much added variability.
format Online
Article
Text
id pubmed-7923309
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79233092021-03-02 Validation of a three-item Fatigue Severity Scale for patients with substance use disorder: a cohort study from Norway for the period 2016–2020 Vold, Jørn Henrik Gjestad, Rolf Aas, Christer F. Meland, Eivind Johansson, Kjell Arne Fadnes, Lars Thore Health Qual Life Outcomes Research BACKGROUND: Little attention has been paid to customising fatigue questionnaires for patients with Substance Use Disorders (SUDs). The present study aims to validate and shorten the nine-item Fatigue Severity Scale (FSS-9) and Visual Analogue Fatigue Scale (VAFS) for use with this population. METHODS: We used data from a nested cohort with annual health assessments with responses on the FSS-9 and VAFS. During the period 2016–2020, 917 health assessments were collected from 655 patients with SUD in Bergen and Stavanger, Norway. A total of 225 patients answered the health assessment at least twice. We defined baseline as the first annual health assessment when the health assessments were sorted chronologically per patient. We checked for internal consistency, and we used longitudinal confirmatory factor analysis (CFA) and linear mixed model (LMM) analysis to validate and shorten the FSS-9 and VAFS. RESULTS: The internal consistency of the FSS-9 was excellent with a Cronbach’s α of 0.94 at baseline and 0.93 at the second annual health assessment. When shortening the FSS-9 to a three-item FSS (FSS-3, items 5–7), the Cronbach’s α was 0.87 at baseline and 0.84 at the second health assessment. The internal consistency was not affected when the VAFS was added to the FSS-3 and the FSS-9. The longitudinal CFA model showed a well-fitting model for the FSS-3 (χ(2) = 13.33, degree of freedom = 8, P = 0.101). The LMM analysis showed equal linear changes at the individual level for the FSS-3 (slope: 0.00, P > 0.05) and FSS-9 (slope: 0.01, P > 0.05) between the health assessments. CONCLUSION: The FSS-9 could be shortened to the FSS-3 with high validity and reliability for patients with SUDs and the addition of VAFS did not provide much added variability. BioMed Central 2021-03-02 /pmc/articles/PMC7923309/ /pubmed/33653349 http://dx.doi.org/10.1186/s12955-021-01708-w Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Vold, Jørn Henrik
Gjestad, Rolf
Aas, Christer F.
Meland, Eivind
Johansson, Kjell Arne
Fadnes, Lars Thore
Validation of a three-item Fatigue Severity Scale for patients with substance use disorder: a cohort study from Norway for the period 2016–2020
title Validation of a three-item Fatigue Severity Scale for patients with substance use disorder: a cohort study from Norway for the period 2016–2020
title_full Validation of a three-item Fatigue Severity Scale for patients with substance use disorder: a cohort study from Norway for the period 2016–2020
title_fullStr Validation of a three-item Fatigue Severity Scale for patients with substance use disorder: a cohort study from Norway for the period 2016–2020
title_full_unstemmed Validation of a three-item Fatigue Severity Scale for patients with substance use disorder: a cohort study from Norway for the period 2016–2020
title_short Validation of a three-item Fatigue Severity Scale for patients with substance use disorder: a cohort study from Norway for the period 2016–2020
title_sort validation of a three-item fatigue severity scale for patients with substance use disorder: a cohort study from norway for the period 2016–2020
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923309/
https://www.ncbi.nlm.nih.gov/pubmed/33653349
http://dx.doi.org/10.1186/s12955-021-01708-w
work_keys_str_mv AT voldjørnhenrik validationofathreeitemfatigueseverityscaleforpatientswithsubstanceusedisorderacohortstudyfromnorwayfortheperiod20162020
AT gjestadrolf validationofathreeitemfatigueseverityscaleforpatientswithsubstanceusedisorderacohortstudyfromnorwayfortheperiod20162020
AT aaschristerf validationofathreeitemfatigueseverityscaleforpatientswithsubstanceusedisorderacohortstudyfromnorwayfortheperiod20162020
AT melandeivind validationofathreeitemfatigueseverityscaleforpatientswithsubstanceusedisorderacohortstudyfromnorwayfortheperiod20162020
AT johanssonkjellarne validationofathreeitemfatigueseverityscaleforpatientswithsubstanceusedisorderacohortstudyfromnorwayfortheperiod20162020
AT fadneslarsthore validationofathreeitemfatigueseverityscaleforpatientswithsubstanceusedisorderacohortstudyfromnorwayfortheperiod20162020
AT validationofathreeitemfatigueseverityscaleforpatientswithsubstanceusedisorderacohortstudyfromnorwayfortheperiod20162020